Luteolin Inhibits <scp>NLRP3</scp> Inflammasome Activation to Ameliorate <scp>DSS</scp> ‐Induced Colitis by Regulating <scp>AMPK</scp> Signalling
Luteolin alleviates DSS-induced ulcerative colitis in mice by targeting the NLRP3 inflammasome, as it shows no effect in NLRP3<sup>-/-</sup> mice. It inhibits NLRP3 activation and IL-1β secretion in macrophages by reducing ROS, mtROS and calcium levels via AMPK binding and signalling. Metabolomic changes suggest lipid metabolism involvement. Luteolin represents a promising NLRP3-targeted therapeutic candidate for UC.
Authors
- Liyan Deng
- Xiandong Lin (ORCID: https://orcid.org/0000-0002-3250-4014)
- Lianxiang Luo (ORCID: https://orcid.org/0000-0002-3391-9713)
- Fangfang Huang (ORCID: https://orcid.org/0000-0001-5398-7978)
- Yiming Sun (ORCID: https://orcid.org/0000-0002-2398-137X)
- Yinglin Liao (ORCID: https://orcid.org/0000-0001-5125-3735)
- Zhuo Chen (ORCID: https://orcid.org/0000-0002-6351-8689)
- Xinming Chen (ORCID: https://orcid.org/0000-0001-8202-8784)
- Guixuan Fang
Institutions
- Guangdong Medical College (CN)
- Guangdong Ocean University (CN)
Publication Details
- Journal
- Cell Proliferation
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1111/cpr.70134
- Citations
- 2
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Natural Science Foundation of China